ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
103 395,93
-0,70%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acadia Pharmaceuticals Inc (ACAD)

  7. Acadia Pharmaceuticals Inc (ACAD) Actualités

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACAD
DateHeureSourceTitreSymboleSociété
17/01/202522h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
14/01/202515h05Business WireAcadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
30/12/202423h37PR Newswire (US)Acadia Pharmaceuticals Set to Join S&P SmallCap 600NASDAQ:ACADAcadia Pharmaceuticals Inc
19/12/202422h05Business WireAcadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025NASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202422h05Business WireAcadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202400h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202400h31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
09/12/202415h00Business WireAcadia Pharmaceuticals Appoints Thomas Garner Chief Commercial OfficerNASDAQ:ACADAcadia Pharmaceuticals Inc
26/11/202422h05Business WireAcadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711NASDAQ:ACADAcadia Pharmaceuticals Inc
21/11/202422h05Business WireAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNASDAQ:ACADAcadia Pharmaceuticals Inc
14/11/202412h48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
06/11/202422h05Business WireAcadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
05/11/202422h05Business WireAcadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
18/10/202400h41Business WireAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202422h07Business WireAcadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202422h07Business WireAcadia Pharmaceuticals annonce l’approbation de DAYBUE™ (trofinétide) par Santé Canada pour le traitement du syndrome de RettNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202423h14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202422h15Business WireCatherine Owen Adams Succeeds Steve Davis as CEO of Acadia PharmaceuticalsNASDAQ:ACADAcadia Pharmaceuticals Inc
20/08/202422h39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
14/08/202414h04Business WireRyan Reynolds Announces More to Parkinson’s® CampaignNASDAQ:ACADAcadia Pharmaceuticals Inc
07/08/202422h30Business WireAcadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
06/08/202422h05Business WireAcadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
24/07/202422h05Business WireAcadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
18/07/202415h04Business WireClinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in MedNASDAQ:ACADAcadia Pharmaceuticals Inc
18/06/202415h04Business WireAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
15/05/202415h05Business WireAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
08/05/202422h05Business WireAcadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
29/04/202422h16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
24/04/202422h05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACAD

Dernières Valeurs Consultées

BOV
V1IP34R
Vipshop
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés